Leukemias and lymphomas: Treatment and prophylaxis of the central nervous system

Current Treatment Options in Neurology

Volumn 8, Issue 4, 2006, Pages 335-345

  Franklin, Janet L ^a   Finlay, Jonathan ^b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DIAZIQUONE; DIGOXIN; ETOPOSIDE; FOLINIC ACID; HYDROCORTISONE; IFOSFAMIDE; LIVE VACCINE; MAFOSFAMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; PHENYTOIN; PROBENECID; RITUXIMAB; ROFECOXIB; SALICYLIC ACID DERIVATIVE; SULFONAMIDE; THIOTEPA; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AGE DISTRIBUTION; ARACHNOIDITIS; ATAXIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLINDNESS; BONE MARROW SUPPRESSION; BONE PAIN; BRAIN LEUKEMIA; BRAIN LYMPHOMA; BURKITT LYMPHOMA; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COGNITIVE DEFECT; CONJUNCTIVITIS; DIETARY INTAKE; DRUG BLOOD LEVEL; DRUG COST; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; HEADACHE; HUMAN; LARGE CELL LYMPHOMA; LEARNING DISORDER; LEUKOENCEPHALOPATHY; LIFESTYLE; LUNG EDEMA; LYMPHOBLASTOMA; MALAISE; MENINGISM; MUCOSA INFLAMMATION; MYALGIA; MYELITIS; NAUSEA; NONHODGKIN LYMPHOMA; PARAPLEGIA; PARESIS; PLEOCYTOSIS; PROGNOSIS; REVIEW; SEIZURE; SOMNOLENCE; TREATMENT PLANNING; VOMITING;

EID: 33745332633     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-006-0023-9     Document Type: Review

References (60)

1. Bleyer WA, Poplack DA: Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Semin Oncol 1985, 12:131-148.
2. Gokbuger N, Hoeltzer D: Meningeosis leukaemica in adult acute lymphoblastic leukemia. J Neurol Oncol 1998, 38:167-180.
3. Keldsen N, Michalski W, Bentzen SM, et al.: Risk factors for central nervous system involvement in non-Hodgkin's lymphoma. Acta Oncol 1996, 35:703-708.
4. Horak ID, Kremer AB, Magrath IT. Management of histologically aggressive lymphomas with a high risk of CNS disease. Baillieres Clin Haematol 1996, 9:707-727.
5. Van Dongen-Melman JE, De Groot A, Van Dongen JJ, et al.: Cranial irradiation is the major cause of learning problems in children treated for leukemia and lymphoma: a comparative study. Leukemia 1997, 11:1197-2000.
6. Haddy TB, Adde MA, McCalla J, et al.: Late effects in long-term survivors of high-grade non-Hodgkin's lymphomas. J Clin Oncol 1998, 16:2070-2079.
7. Claviez A, Neubauer B, Link J, Scheppenheim R: Intracerebral hemorrhage as a late complication after CNS treatment of childhood lymphoma. Klin Padiatr 1998, 210:406-408.
8. Loning L, Zimmerman M, Reiter A, et al.: Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood 2000, 95:2770-2775.
9. Margolin JF, Poplack DG: Acute lymphoblastic leukemia. In Principles and Practice of Pediatric Oncology, edn 5. Philadelphia: Lippincott Williams and Wilkins; 2005.
10. Sham RL, Phatak PD, Kouides PA, et al.: Hematologic neoplasia and the central nervous system. Am J Hematol 1999, 62:234-238.
11. Sheehan T, Cuthbert RJG, Parker AC: Central nervous system involvement in haematological malignancies. Clin Lab Haematol 1989, 11:331-338.
12. Bruyn GAW, Zwetsloot CP, van Nieuwkoop JA, et al.: Cranial nerve palsy as a presenting feature of secondary plasma cell leukemia. Cancer 1987, 60:906-909.
13. Pinkel D, Woo S: Prevention and treatment of meningeal leukemia in children. Blood 1994, 84:355-366.
14. Nesbit ME, Sather H, Robinson LL, et al.: Sanctuary therapy: a randomized trial of 724 children with previously untreated acute lymphoblastic leukemia: a report from the Children's Cancer Group. Cancer Res 1982, 42:674-680.
15. Schrappe M, Reiter A, Riehm H: Prophylaxis and treatment of neoplastic meningeosis in childhood acute lymphoblastic leukemia. J Neurooncol 1998, 38:159-165.
16. Gibson BES, Wheatley K, Hann IM, et al.: Treatment strategy and long term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2000, 19:2130-2138.
17. Pui CH, Evans WE: Acute lymphoblastic leukemia. N Engl J Med 1998, 339:605-615.
18. Duval M, Suciu S, Ferster A, et al.: Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organization for Research and Treatment of Cancer-Children's Leukemia group phase 3 trial. Blood 2002, 99:2734-2739.
19. Bostrom BC, Sensel MR, Sather H, et al.: Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003, 101:3809-3817.
20. Mitchell CD, Richards SM, Kinsey SE, et al.: Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukemia: results of the UK Medical Research Council ALL97 randomized trial. Brit J Haematol 2005, 129:734-745.
21. Nesbit ME, Robison LL, Littman PS, et al.: Presymptomatic central nervous system therapy in previously untreated childhood acute lymphoblastic leukemia: comparison of 1800 rad and 2400 rad. A report from the Children's Cancer Study Group. Lancet 1981, 8218:461-466.
22. Bleyer WA, Sather HN, Nickerson HJ, et al.: Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low risk childhood acute lymphoblastic leukemia: a report of the CCG 106 study by the Children's Cancer Group. J Clin Oncol 1991, 9:1012-1021.
23. Tubergen DG, Gilchrist GS, O'Brien RT, et al.: Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features. J Clin Oncol 1993, 11:527-537.
24. Nachman JB, Sather HN, Sensel MG, et al.: Augmented post-induction therapy for children with high risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998, 338:1663-1671.
25. Cortes J, O'Brien SM, Pierce S, et al.: The value of high dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 1995, 86:2091-2097.
26. Kantarjian HM, O'Brien S, Smith TL, et al.: Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphoblastic leukemia. J Clin Oncol 2000, 18:547-561.
27. Pui CH, Dahl GV, Kalwinsky DK, et al.: Central nervous system leukemia in children with acute nonlymphoblastic leukemia. Blood 1985, 66:1062-1067.
28. Stevens RF, Hann IM, Wheatley K, et al.: Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. Br J Haematol 1998, 101:130-140.
29. Woods WG, Neudorf S, Gold S, et al.: A comparison of allogeneic bone marrow transplant, autologous bone marrow transplant, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001, 97:56-62.
30. Creutzig U, Ritter J, Zimmermann M, et al.: Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol 2001, 19:2705-2713.
31. Abbott BL, Rubnitz JE, Tong X, et al.: Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: a single institutions experience. Leukemia 2003, 17:2090-2096.
32. Bisschop MM, Revesz T, Bierings M, et al.: Extramedullary infiltrates at diagnosis have no prognostic significance in children with acute myeloid leukemia. Leukemia 2001, 15:46-49.
33. Cassileth PA, Sylvester LS, Bennett JM, et al.: High peripheral blast count in adult acute myelogenous leukemia is a primary risk factor for CNS leukemia. J Clin Oncol 1988, 6:495-500.
34. Bishop JF, Matthews JP, Young GA, et al.: A randomized study of high dose cytarabine in induction in acute myeloid leukemia. Blood 1996, 87:1710-1717.
35. Herzig RH: High dose ara-C in older adults with acute leukemia. Leukemia 1996, 10(Suppl 1):Sl0-S11.
36. Castagnola C, Nozza A, Corso A, et al.: The value of combination therapy in adult acute myeloid leukemia with central nervous system involvement. Haematologica 1997, 82:577-580.
37. Cairo MS, Sposto R, Perkins SL, et al.: Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience. Brit J Haematol 2003, 120:660-670.
38. Gururangan S, Sposto R Cairo MS, et al.: Outcome of CNS disease at diagnosis in disseminated small noncleaved-cell lymphoma and B-cell leukemia: a Children's Cancer Group Study. J Clin Oncol 2000, 18:2017-2025.
39. Patte C, Michon J, Behrendt H, et al.: Results of the LMB 89 protocol for childhood 13-cell lymphoma and leukemia (ALL). Study of the SFOP. Med Pediatr Oncol 1997, 27:358.
40. Reiter A, Schrappe M, Tiemann M, et al.: Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy; a report of the Berlin-Frankfurt-Munster Group trial NHL BFM 90. Blood 1999, 94:3294-3306.
41. Sandlund JT, Murphy SB, Santana VM, et al.: CNS involvement in children with newly diagnosed non-Hodgkin's lymphoma. J Clin Oncol 2000, 18:3018-3024.
42. Burkhardt B, Woessmann W, Zimmerman M, et al.: Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol 2006, 24:491-499.
43. Cairo MS, Sposto R, Hoover-Regan M, et al.: Childhood and adolescent large cell lymphoma: a review of the Children's Cancer Group experience. Am J Hematol 2003, 72:53-63.
44. Laver JH, Kraveka JM, Hutchinson RE, et al.: Advanced stage large cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate dose methotrexate and high dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol 2005, 23:541-547.
45. Blaney S, Poplack D: New cytotoxic drugs for intrathecal administration. J Neurooncol 1998, 38:219-223.
46. Gaynon PS, Angiolillo AL, Franklin JL, Reaman GH: Childhood Acute Lymphoblastic Leukemia in Cancer Medicine, edn 7. Hamilton, Ontario: Holland-Frei; 2006.
47. Blaney S, Balis F, Murphy R, et al.: A phase 1 study of intrathecal mafosfamide in patients with refractory meningeal malignancies. Proc Am Soc Clin Oncol 1992, 11:113.
48. Slavc I, Schuller E, Czech T et al.: Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination. J Neurooncol 1998, 38:213-218.
49. Slavc I, Schuller E, Falger J, et al.: Feasibility of longterm intraventricular therapy with mafosfamide and etoposide: experience in 26 children with disseminated malignant brain tumors. J Neurooncol 2003, 64:239-247.
50. Blaney S, Heideman R, Berg S, et al.: Phase 1 clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol 2003, 21:143-147.
51. Berg S, Balis F, Zimm S, et al.: Phase I/II trial and pharmacoknetics of intrathecal diaziquone in refractory meningeal malignancies. J Clin Oncol 1992, 10:143-148.
52. Sandor V, Stark-Vancs V, Peterson D, et al.: Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 1999, 16:3000-3006.
53. Soussain C, Suzan F, Hoang-Xuan K, et al.: Results of intensive chemotherapy followed by hematopoietic stem cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001, 19:742-749.
54. Cheng T, Forsyth P, Chaudhry A, et al.: High-dose thiotepa, busulfan, cydophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 2003, 31:679-685.
55. Pels H, Schulz H, Mapke O, et al.: Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J Neurooncol 2002, 59:213-216.
56. Pels H, Schultz H, Schlegel U, et al.: Treatment of CNS lymphoma with the anti-CD 20 antibody rituximab: experience with two cases and review of the literature. Onkologie 2003, 26:351-354.
57. Rubenstein JL, Combs D, Rosenberg J, et al.: Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003, 101:466-468.
58. Bomgaars L, Geyer JR, Franklin J, et al.: Phase 1 trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol 2004, 22:3916-3921.
59. Glantz MJ, LaFollette S, Jaeckle KA, et al.: Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999, 17:3110-3116.
60. Mosher AM, Adamson PC, Gillespie AJ, et al.: Intraventricular concentration times time (C × T) methotrexate and cytarabine for patients with recurrent meningeal leukemia and lymphoma. Cancer 1999, 85:511-516.